NASDAQ:BGNE

BeiGene (BGNE) News Headlines

$194.47

+3.39 (+1.77%)

(As of 08/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $183.82
▼
$199.16
50-Day Range: $130.30
▼
$194.48
52-Week Range: $118.18
▼
$426.56

Volume: 225,669 shs
Average Volume: 251,293 shs
Market Capitalization: $20.11 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $300.33

Get BeiGene News Delivered to You Automatically

BGNE Media Mentions By Week

BGNE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BGNE
News Sentiment
▼
-0.06

0.34
▲
Average
Medical
News Sentiment

BGNE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BGNE Articles
This Week
▼
10

6
▲
BGNE Articles
Average Week

Source

Source	Headline
	BeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages marketbeat.com - August 3 at 3:26 AM
	Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) Target Price at $300.33 americanbankingnews.com - August 6 at 3:32 AM
	U.S.-listed shares of BeiGene rise after Q2 revenue more than doubles Y/Y seekingalpha.com - August 5 at 8:43 AM
	Recap: BeiGene Q2 Earnings - Benzinga benzinga.com - August 4 at 3:55 PM
	BeiGene GAAP EPADS of -$5.56 misses by $1.45, revenue of $341.57M beats by $30.5M - Seeking Alpha seekingalpha.com - August 4 at 10:54 AM
	BeiGene Reports Second Quarter 2022 Financial Results - Business Wire businesswire.com - August 4 at 10:54 AM
	BeiGene Reports Second Quarter 2022 Financial Results finance.yahoo.com - August 4 at 10:54 AM
	Why BeiGene (BGNE) Might Surprise This Earnings Season finance.yahoo.com - August 3 at 2:41 PM
	BeiGene (NASDAQ:BGNE) Shares Gap Down to $168.08 americanbankingnews.com - August 3 at 5:40 AM
	Research Analysts Offer Predictions for BeiGene, Ltd.'s Q2 2022 Earnings (NASDAQ:BGNE) americanbankingnews.com - July 30 at 1:16 AM
	Jack Ma's Alibaba among hundreds of Chinese firms facing delisting - New York Post nypost.com - July 29 at 6:48 PM

	AbbVie Slides After Cutting Sales Outlook on Cancer Drug Decline - Bloomberg bloomberg.com - July 29 at 1:46 PM
	What's in the Cards for Sesen Bio's (SESN) Q2 Earnings? - Nasdaq nasdaq.com - July 27 at 7:39 PM
	BeiGene (NASDAQ:BGNE) PT Lowered to $293.00 americanbankingnews.com - July 18 at 3:52 AM
	BeiGene (NASDAQ:BGNE) Stock Price Down 4.3% americanbankingnews.com - July 15 at 7:48 AM
	Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst finance.yahoo.com - July 14 at 7:07 PM
	FDA defers action on Novartis/BeiGene tislelizumab for esophagus cancer citing inspection - Seeking Alpha seekingalpha.com - July 14 at 2:06 PM
	Beigene Says FDA Defers Action on BLA Due to Covid Travel Restrictions - MarketWatch marketwatch.com - July 14 at 2:06 PM
	Absci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires - Yahoo Finance finance.yahoo.com - July 14 at 9:06 AM
	BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC - Business Wire businesswire.com - July 14 at 9:06 AM
	BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC finance.yahoo.com - July 14 at 9:06 AM
	BeiGene Appoints Chan Lee as General Counsel - Business Wire businesswire.com - July 13 at 8:41 PM
	BeiGene Appoints Chan Lee as General Counsel finance.yahoo.com - July 13 at 10:41 AM
	Is BeiGene (BGNE) a Smart Long-Term Investment? finance.yahoo.com - July 12 at 8:08 PM
	Leap Therapeutics (LPTX) and BeiGene (BGNE) Initiate New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer - StreetInsider.com streetinsider.com - July 12 at 8:02 AM
	Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer finance.yahoo.com - July 12 at 8:02 AM
	ADRs End Lower; BeiGene, JinkoSolar Trade Actively - MarketWatch marketwatch.com - July 6 at 10:46 PM
	BeiGene in pact with InnoRNA to develop messenger RNA-based therapies (NASDAQ:BGNE) - Seeking Alpha seekingalpha.com - July 6 at 10:46 PM
	BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Business Wire businesswire.com - July 6 at 9:04 AM
	With just 16 new drugs approved in H1 2022, FDA poised for slew of approvals in H2 (BMY) - Seeking Alpha seekingalpha.com - July 3 at 6:12 PM
	Myeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D. - Yahoo Finance finance.yahoo.com - June 30 at 10:35 AM
	BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Business Wire businesswire.com - June 30 at 4:55 AM

	BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma finance.yahoo.com - June 30 at 4:55 AM
	Dunad Therapeutics Appoints Industry Veteran Pearl Huang as Chief Executive Officer - Yahoo Finance finance.yahoo.com - June 28 at 7:41 AM
	Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More - Nasdaq nasdaq.com - June 22 at 3:27 PM
	Why Shares of BeiGene Popped Today - The Motley Fool fool.com - June 22 at 10:27 AM
	BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock? finance.yahoo.com - June 22 at 10:27 AM
	Why Shares of BeiGene Popped Today finance.yahoo.com - June 21 at 7:25 PM
	BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab - Business Wire businesswire.com - June 21 at 7:16 AM
	BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab finance.yahoo.com - June 21 at 7:16 AM
	BeiGene (BGNE) Announces PDUFA Extension for sNDA for BRUKINSA for the Treatment of CLL/SL - StreetInsider.com streetinsider.com - June 13 at 8:45 PM
	Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer - Business Wire businesswire.com - June 13 at 10:44 AM
	BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets - Business Wire businesswire.com - June 13 at 10:44 AM
	BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL finance.yahoo.com - June 13 at 10:44 AM
	BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets finance.yahoo.com - June 13 at 10:44 AM
	BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress - Yahoo Finance finance.yahoo.com - June 12 at 5:03 AM
	BeiGene stock rises as tislelizumab gets approval in China for head/neck cancer subtype - Seeking Alpha seekingalpha.com - June 10 at 5:09 PM
	China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer - Business Wire businesswire.com - June 10 at 8:36 AM
	BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress - Business Wire businesswire.com - June 10 at 8:36 AM
	China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer finance.yahoo.com - June 10 at 8:36 AM
	BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress finance.yahoo.com - June 10 at 8:36 AM

Get BeiGene News Delivered to You Automatically

This page (NASDAQ:BGNE) was last updated on 8/7/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms